ASX:NOX
Market Cap:
Price Delay ~20min
Interactive 2020
Annual Report

Media

24-Dec-2020

Australian Financial Services company, Reach Markets, interviewed CEO Dr Graham Kelly for their December Newsletter.

To read more click here;

6-Dec-2020

Health Industry Hub, Australian digital news site for Pharma, MedTech and Biotech industries and key industry stakeholders, informed;

Click here to read further

3-Dec-2020

French language news site dedicated to health technologies, Biotech Finances, covered the recent announcement;

Click here to read more

3-Dec-2020

A resource for life-sciences executives and other healthcare-service related professionals" posted the following News Release;

Click here to read more

3-Dec-2020

BioSpace, the Life Science industry digital news and information source reported,

Click here to read more

2-Dec-2020

Australian Financial Review's Street Talk wrote, Noxopharm Targets A$20M Deal for Clinical Studies

Click here to read more

16-Nov-2020

TrialSite News, the digital media news site dedicated to coverage of clinical research trials, reported the following, “Australian clinical-stage drug development company Noxopharm (ASX: NOX) is pleased to announce it has joined with Bristol Myers Squibb (NYSE: BMY) in an Australian pilot study investigating the ability of Noxopharm’s immunotherapy drug candidate, Veyonda®, to overcome resistance to Bristol Myers Squibb’s nivolumab (Opdivo®) in the treatment of cancer.”

Click here to read more

13-Nov-2020

Australian stock market digital news site, The Market Herald, reported "Major breakthrough validates Noxopharm's(ASX:NOX) cancer therapy", following the November 13, 2020 ASX announcement regarding independent Weill Cornell Medical College research.

Click here to read more

13-Nov-2020

Investing.com(AU) mentioned in a Brief: Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product

Click here to read more

13-Nov-2020

Yahoo!Finance noted Noxopharm’s (ASX:NOX) announcement regarding the planned pilot study with Bristol Myers Squibb (BMS) using NOX’s lead drug candidate, Veyonda, and the BMS drug, Opdivo.

Click here to read more